BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2004

View Archived Issues

Statins may promote new bone formation via induction of PI3K signaling pathway

Read More

News in Context, a new feature of DailyDrugNews.com

Read More

Broccoli derivative shows cytotoxicity in bladder and prostate cancer cell lines / News in Context

Read More

Two series of glucokinase activators reported by OSI scientists

Read More

Novel PEPCK inhibitors prepared and tested at Roche

Read More

New xanthine-based adenosine A1 antagonists covered by Endacea patent

Read More

New analgesic agents identified by Italian researchers

Read More

Roche presents new anti-HIV reverse transcriptase inhibitors

Read More

Novel inhibitors of EGFR-mediated signal transduction claimed by Boehringer Ingelheim

Read More

New anti-HIV agents in early development at Janssen

Read More

Encysive presents new urotensin II/CCR9 antagonists and their use

Read More

Enrollment completed in adult insomnia phase II study of SO-101

Read More

alpha-TEA and vitamin E succinate active in preclinical cancer models

Read More

Launches and court orders for generic gabapentin

Read More

Approval for new Cancidas indication

Read More

DX-88 granted fast track designation for HAE

Read More

Proof-of-concept study of NPS-1776 in migraine fails to meet primary endpoint

Read More

Tripep completes preclinical safety studies for alpha-HGA

Read More

Expert analysis supports continued development of ENT-103

Read More

Extension study results for PBT-1 in Alzheimer's

Read More

Fast track designation for StaphVAX

Read More

Dynogen licenses compounds from Newron

Read More

Phase I study for PowderMed's novel therapeutic herpes simplex 2 DNA vaccine

Read More

Fast track designation for FK-228 for CTCL

Read More

Positive phase I findings for CTI-01

Read More

European orphan drug designation for TheraCLEC

Read More

Positive preliminary results for phase I study of oral PTH

Read More

New two-part phase I trial with ThGLP-1

Read More

Aviscumine shows antitumor effects and a good safety profile in refractory cancer patients

Read More

Oral CP-547632 shows promise in the treatment of advanced solid tumors

Read More

SB-715992 dose-dependently reduces ANC in patients with solid tumors

Read More

Long-term octreotide restores gonadal function in male patients with acromegaly

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing